Foundation Medicine-B (02616.HK) announced that it will release the blockbuster product CS5001 (ROR1 ADC) 2.0 for lymphoma at the 66th American Society of Hematology (ASH) annual meeting, unveiling the latest clinical data.

The announcement stated that CS5001 is currently the first ROR1 ADC observed to have clinical efficacy in both solid tumors and lymphomas. This year's ASH conference highlights the latest safety and efficacy data of CS5001 as monotherapy for advanced lymphomas.

In addition, the disclosure at the ASH annual meeting emphasized the latest safety and efficacy data of CS5001 as monotherapy for advanced lymphomas. Furthermore, the global multicenter clinical trial of CS5001 is currently being conducted simultaneously in the USA, Australia, and China, with dose escalation completed. The company will soon initiate an Ib phase dose expansion study covering multiple tumor types with registration potential.

~